Open in Screener

NEUE

NeueHealth Inc

Oct 02 • 04:00PM ET

6.75

0.00 0.00 %

Healthcare • Healthcare Plans • USA • NYSE

Peers: UNH CI HUM CNC MOH HCA THC UHS ACHC CRL

Index	-	P/E	-	EPS (ttm)	-15.97	Insider Own	66.66%	Shs Outstand	9.02M	Perf Week	0.64%
Market Cap	60.91M	Forward P/E	-	EPS next Y	-	Insider Trans	-0.55%	Shs Float	3.01M	Perf Month	0.49%
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	6.99%	Short Float	0.56%	Perf Quarter	-1.70%
Income	-134.80M	P/S	0.07	EPS this Y	-	Inst Trans	-	Short Ratio	2.70	Perf Half Y	2.32%
Sales	890.44M	P/B	-	EPS next Y	-	ROA	-11.55%	Short Interest	0.02M	Perf YTD	-8.99%
Book/sh	-151.72	P/C	-	EPS next 5Y	-	ROE	-	52W High	7.66 -11.84%	Perf Year	29.37%
Cash/sh	-	P/FCF	-	EPS past 3/5Y	46.84% -7.17%	ROIC	-	52W Low	3.79 78.18%	Perf 3Y	-92.66%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-14.77% 27.26%	Gross Margin	-	Volatility	1.63% 2.12%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	87.09%	Oper. Margin	-3.26%	ATR (14)	0.15	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-13.83%	Profit Margin	-15.14%	RSI (14)	53.05	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.70	EPS Q/Q	69.74%	SMA20	0.42%	Beta	0.60	Target Price	7.00
Payout	-	Debt/Eq	-	Sales Q/Q	-7.48%	SMA50	0.74%	Rel Volume	0.00	Prev Close	6.75
Employees	986	LT Debt/Eq	-	Earnings	Aug 07 BMO	SMA200	0.13%	Avg Volume	6.29K	Price	6.75
IPO	Jun 24, 2021	Option/Short	No / No	EPS/Sales Surpr.	-1427.27% -4.44%	Trades		Volume	180	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-11-22	Downgrade	JP Morgan	Neutral → Underweight
Mar-29-22	Downgrade	JP Morgan	Overweight → Neutral
Mar-04-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$9 → $3
Mar-02-22	Downgrade	BofA Securities	Buy → Underperform
Jan-10-22	Resumed	Citigroup	Neutral	$5 → $3.50
Dec-16-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$5 → $4
Dec-14-21	Initiated	Goldman	Neutral	$5
Dec-10-21	Upgrade	JP Morgan	Neutral → Overweight	$6
Nov-12-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$13 → $5
Nov-02-21	Downgrade	Cowen	Outperform → Market Perform	$14 → $9
Nov-01-21	Downgrade	Citigroup	Buy → Neutral
Sep-10-21	Initiated	Cowen	Outperform	$14
Aug-04-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$12
Aug-04-21	Upgrade	Citigroup	Neutral → Buy	$16 → $12
Jul-19-21	Initiated	Wolfe Research	Peer Perform	$15
Jul-19-21	Initiated	RBC Capital Mkts	Outperform	$22
Jul-19-21	Initiated	Piper Sandler	Overweight	$24
Jul-19-21	Initiated	Morgan Stanley	Equal-Weight	$18
Jul-19-21	Initiated	JP Morgan	Neutral	$19
Jul-19-21	Initiated	Goldman	Buy	$36

Show Previous Ratings

Oct-02-25 09:16AM	NeueHealth Announces Closing of Take-Private Transaction (Business Wire)
Aug-07-25 06:56AM	NeueHealth: Q2 Earnings Snapshot (Associated Press Finance)
06:45AM	NeueHealth Reports Second Quarter 2025 Results (Business Wire)
Jul-17-25 08:00AM	NeueHealth to Host Second Quarter 2025 Earnings Conference Call on August 7, 2025 (Business Wire)
Jul-16-25 06:45AM	Premier Medical Collaborates with Walgreens to Expand Access to Care Across Central Florida (Business Wire)
11:28AM	Loading…
Jun-02-25 11:28AM	Elevation Point Adds Former Orion CEO Eric Clarke to Board of Directors (Wealth Management)
May-09-25 03:13AM	NeueHealth Inc (NEUE) Q1 2025 Earnings Call Highlights: Strong Consumer Growth and Continued ... (GuruFocus.com)
May-08-25 06:45AM	NeueHealth Reports First Quarter 2025 Results (Business Wire)
Apr-23-25 08:00AM	NeueHealth to Host First Quarter 2025 Earnings Conference Call on May 8, 2025 (Business Wire)
Mar-20-25 01:14PM	NeueHealth, Inc (NEUE) Q4 2024 Earnings Call Transcript (SeekingAlpha) +8.88%
06:45AM	NeueHealth Reports Fourth Quarter and Full Year 2024 Results (Business Wire)
Feb-26-25 08:00AM	NeueHealth to Host Fourth Quarter 2024 Earnings Conference Call on March 20, 2025 (Business Wire)
Dec-23-24 05:53PM	NeueHealth to Be Taken Private by NEA and Consortium of Investors (Business Wire) +12.83% +74.94%
Nov-07-24 06:45AM	Neuehealth Reports Third Quarter 2024 Results (Business Wire) +6.36%
Oct-30-24 06:45AM	NeueHealth Acquires Full Ownership of Centrum Health (Business Wire)
08:00AM	Loading…
Oct-17-24 08:00AM	NeueHealth to Host Third Quarter 2024 Earnings Conference Call on November 7, 2024 (Business Wire) -5.68%
Sep-19-24 12:00PM	NeueHealth (NEUE) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +6.94%
Aug-07-24 06:45AM	NeueHealth Reports Second Quarter 2024 Results (Business Wire)
Jul-18-24 08:00AM	NeueHealth to Host Second Quarter 2024 Earnings Conference Call on August 7, 2024 (Business Wire)
Jun-24-24 06:45AM	NeueHealth Secures up to $150 Million in New Term Loan Facility with Hercules Capital (Business Wire)
Jun-18-24 04:30PM	NeueHealth Receives NYSE Non-Compliance Letter Regarding Market Capitalization Requirements (Business Wire)
Jun-06-24 07:47AM	NEUE Stock Earnings: NeueHealth Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
May-11-24 08:41AM	NeueHealth, Inc. (NYSE:NEUE) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 06:45AM	NeueHealth Reports First Quarter 2024 Results (Business Wire)
Apr-18-24 08:00AM	NeueHealth to Host First Quarter 2024 Earnings Conference Call on May 8, 2024 (Business Wire) +8.05%
Apr-09-24 05:29PM	NeueHealth Enters into Amendment to its Credit Facility (Business Wire) +6.57%
Mar-06-24 08:01AM	NEUE Stock Earnings: NeueHealth Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +18.13%
06:45AM	NeueHealth Reports Fourth Quarter and Full Year 2023 Results (Business Wire)
Feb-20-24 08:00AM	NeueHealth to Host Fourth Quarter 2023 Earnings Conference Call on March 6, 2024 (Business Wire)
Jan-18-24 05:38AM	Bright Health rebrands as NeueHealth, distances itself from insurance portfolio (Healthcare Dive)
04:05PM	Loading…
Jan-17-24 04:05PM	Bright Health Group Adopts NeueHealth as Corporate Brand Name (Business Wire)
Jan-02-24 04:30PM	Bright Health Group Closes the Sale of its California Medicare Advantage Business to Molina Healthcare (Business Wire) +8.13% +10.91%
Dec-29-23 06:45AM	Bright Health Group Strengthens Capital Position with Amendment to its Credit Facility, Impending Close of the Sale of its California Medicare Advantage Business (Business Wire) +45.06%
Nov-09-23 01:23PM	Bright Health Group, Inc. (NYSE:BHG) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 09:33AM	Bright Health: Q3 Earnings Snapshot (Associated Press Finance)
07:26AM	Bright Health Group Inc (BHG) Reports Q3 2023 Earnings: Revenue Up 39% YoY, Net Loss of $479. ... (GuruFocus.com)
06:45AM	Bright Health Group Reports Third Quarter 2023 Results (Business Wire)
Oct-13-23 08:00AM	Bright Health Group to Host Third Quarter 2023 Earnings Conference Call on November 7, 2023 (Business Wire)
Sep-19-23 06:45AM	Bright Health Group Continues to Make Significant Progress Towards ACA Insurance Business Wind-Down (Business Wire)
Aug-09-23 08:53PM	Q2 2023 Bright Health Group Inc Earnings Call (Thomson Reuters StreetEvents) -12.34% -10.84%
08:05AM	Bright Health Group (BHG) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
06:54AM	Bright Health: Q2 Earnings Snapshot (Associated Press Finance)
06:45AM	Bright Health Group Reports Second Quarter 2023 Results (Business Wire)
Aug-07-23 06:45AM	Bright Health Group Secures Financing to Support Operations Pending the Expected Close of California Medicare Advantage Business Sale (Business Wire)
Aug-02-23 08:15AM	Bausch + Lomb (BLCO) Beats Q2 Earnings and Revenue Estimates (Zacks)
Jul-17-23 08:00AM	Bright Health Group to Host Second Quarter 2023 Earnings Conference Call on August 9, 2023 (Business Wire)
Jul-13-23 06:20AM	Investors in Bright Health Group (NYSE:BHG) from a year ago are still down 89%, even after 26% gain this past week (Simply Wall St.) -5.61%
Jul-12-23 03:29PM	A 1,462% Bet on Tiny Health-Care Firm Shows Option Math Is Hard (Bloomberg) +6.25%
Jul-03-23 12:24PM	Molina (MOH) to Buy Bright Health's California Medicare Business (Zacks) -7.94%
08:41AM	Strength Seen in Bright Health (BHG): Can Its 11.9% Jump Turn into More Strength? (Zacks)
Jun-30-23 06:45AM	Bright Health Group Enters into Definitive Agreement with Molina Healthcare to Sell its California Medicare Advantage Business, Bolstering Capital Position to Continue Advancing its Value-Driven Care Model (Business Wire) +11.90%
Jun-09-23 07:59AM	11 Best Health Insurance Stocks to Buy (Insider Monkey)
May-09-23 08:05AM	Bright Health Group (BHG) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +52.94%
06:57AM	Bright Health: Q1 Earnings Snapshot (AP Finance)
06:45AM	Bright Health Group Reports First Quarter 2023 Results (Business Wire)
May-03-23 05:00PM	Bright Health Group Appoints Jay Matushak as Chief Financial Officer (Business Wire)
Apr-28-23 08:00AM	Bright Health Group to Explore Strategic Alternatives for Medicare Advantage Business as it Focuses on Driving Performance through its Consumer Care Delivery Business (Business Wire)
Apr-25-23 04:05PM	Bright Health Group to Host First Quarter 2023 Earnings Conference Call on May 9, 2023 (Business Wire)
Mar-29-23 07:20AM	Bright Health Group, Inc.'s (NYSE:BHG) market cap dropped US$31m last week; Private equity firms bore the brunt (Simply Wall St.)
Mar-02-23 09:19PM	Bright Health Group, Inc. (NYSE:BHG) Q4 2022 Earnings Call Transcript (Insider Monkey) -8.16%
05:38AM	Bright Health Group Full Year 2022 Earnings: US$1.23 loss per share (vs US$3.02 loss in FY 2021) (Simply Wall St.)
02:30AM	Q4 2022 Bright Health Group Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-01-23 08:05AM	Bright Health Group (BHG) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -42.05%
06:45AM	Bright Health Group Reports Fourth Quarter and Full Year 2022 Results (Business Wire)
Feb-22-23 08:05PM	Icon PLC (ICLR) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
Feb-14-23 07:08AM	Bullish Bright Health Group, Inc. (NYSE:BHG) insiders filled their treasuries with US$1.4m worth of stock over last year (Simply Wall St.)
Feb-10-23 01:50PM	25 Biggest Minnesota Companies and Stocks (Insider Monkey)
08:00AM	Bright Health Group to Host Fourth Quarter 2022 Earnings Conference Call on March 1, 2023 (Business Wire)
Feb-01-23 03:15PM	Bright Health plans 2nd round of layoffs at Bloomington headquarters (American City Business Journals) +7.35%
Jan-18-23 05:51AM	Bright Health Group (NYSE:BHG) shareholders are up 31% this past week, but still in the red over the last year (Simply Wall St.) -16.34%
Jan-10-23 07:00AM	Bright Health Group Announces Updated 2023 Expectations Ahead of J.P. Morgan Healthcare Conference Presentation (Business Wire) +25.23%
Jan-04-23 12:00PM	Bright Health (BHG) Upgraded to Buy: Here's What You Should Know (Zacks)
Dec-21-22 08:46AM	Bright Health Group to Present at 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-22 04:30PM	Bright Health Group Receives Continued Listing Standard Notice from NYSE (Business Wire) +5.93% -16.12%
Nov-10-22 04:30PM	CORRECTING and REPLACING Bright Health Group Reports Third Quarter 2022 Results (Business Wire) +14.26% -8.54%
Nov-09-22 03:37PM	NeueHealth and Medical Home Network Partner to Reduce Health Care Disparities through New ACO REACH Model (PR Newswire) -8.75%
02:42PM	Bright Health to lay off 99 local employees after individual health insurance exit (American City Business Journals)
08:05AM	Bright Health Group (BHG) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-07-22 08:05AM	Viatris (VTRS) Q3 Earnings Beat Estimates (Zacks)
Oct-19-22 07:30AM	Bright Health Group to Host Third Quarter 2022 Earnings Conference Call on November 9, 2022 (Business Wire) -6.76%
Oct-18-22 07:30AM	Bright Health Group Announces Closing of $175 Million Capital Raise to Support Focused Business (Business Wire)
Oct-11-22 03:16PM	Bright Health drops individual health insurance business, raises $175M (American City Business Journals) +28.57%
07:00AM	Bright Health Group to Further Focus on Delivering Affordable Healthcare to Aging and Underserved Populations Through Its Fully Aligned Care Model in Florida, Texas, and California (Business Wire)
Sep-13-22 02:22PM	Bright Health Group, Inc.'s (NYSE:BHG) market cap surged US$157m last week, private equity firms who have a lot riding on the company were rewarded (Simply Wall St.) -9.52%
Aug-10-22 04:00PM	Bright Health Group, Inc. (BHG) Q2 2022 Earnings Call Transcript (Motley Fool) -11.86%
07:55AM	Bright Health Group (BHG) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
06:45AM	Bright Health Group Reports Second Quarter 2022 Results (Business Wire)
Aug-08-22 05:45PM	DermTech, Inc. (DMTK) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-05-22 03:06PM	The List: Minnesota CEOs ranked by total compensation (American City Business Journals)
Aug-04-22 06:15PM	Doximity (DOCS) Tops Q1 Earnings and Revenue Estimates (Zacks)
Jul-26-22 08:00AM	Bright Health Group to Host Second Quarter 2022 Earnings Conference Call on August 10, 2022 (Business Wire)
Jul-25-22 05:45PM	Medpace (MEDP) Q2 Earnings and Revenues Top Estimates (Zacks)
Jul-22-22 11:25AM	Bright Health Group (NYSE:BHG) shareholders are up 7.0% this past week, but still in the red over the last year (Simply Wall St.) -7.07%
Jun-22-22 11:18AM	Bright Health Group, Inc. (NYSE:BHG) insiders need another US$3.3m to breakeven on a US$4.5m stock purchase even after recent gains (Simply Wall St.)
May-17-22 04:05PM	Bright Health Group Expands Executive Team as It Drives Performance in Scaled Businesses (Business Wire)
May-08-22 08:21AM	Analysts Have Been Trimming Their Bright Health Group, Inc. (NYSE:BHG) Price Target After Its Latest Report (Simply Wall St.)
May-04-22 04:01PM	Bright Health Group, Inc. (BHG) Q1 2022 Earnings Call Transcript (Motley Fool) +33.33%
06:45AM	Bright Health Group Reports First Quarter 2022 Results (Business Wire)
Apr-19-22 08:30AM	Bright Health Group to Host First Quarter 2022 Earnings Conference Call on May 4, 2022 (Business Wire)
Apr-14-22 05:26PM	True Health parent company to discontinue insurance plans for New Mexicans (American City Business Journals) -5.91%

NeueHealth, Inc. engages in the provision of healthcare products and services for consumers and care providers in local markets. The firm offers individual, family, and Medicare advantage health plans. It operates through the NeueCare and NeueSolutions segments. The NeueCare segment delivers healthcare to all populations across the ACA marketplace, Medicare, and Medicaid through owned and affiliated clinics. The NeueSolutions segment provides a suite of technology, services, and clinical care solutions. The company was founded by Robert J. Sheehy, Tomas Valdivia, and Kyle Rolfing in 2015 and is headquartered in Doral, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Makhzoumi Mohamad	Director	Oct 02 '25	Option Exercise	0.01	3,948,675	39,487	2,385,055	Oct 06 05:54 PM
SANDELL SCOTT D	Director	Oct 02 '25	Option Exercise	0.01	1,116,765	11,168	2,385,055	Oct 06 05:54 PM
SANDELL SCOTT D	Director	Oct 02 '25	Sale	6.75	4,195	28,316	488,702	Oct 06 05:54 PM
Florence Anthony A. Jr.	Director	Oct 02 '25	Option Exercise	0.01	1,116,765	11,168	2,385,055	Oct 06 05:53 PM
Florence Anthony A. Jr.	Director	Oct 02 '25	Sale	6.75	4,195	28,316	488,702	Oct 06 05:53 PM
Walker Paul Edward	Director	Oct 02 '25	Option Exercise	0.01	682,468	6,825	2,385,055	Oct 06 05:53 PM
Walker Paul Edward	Director	Oct 02 '25	Sale	6.75	3,915	26,426	488,702	Oct 06 05:53 PM
Chang Carmen	Director	Oct 02 '25	Option Exercise	0.01	682,468	6,825	2,385,055	Oct 06 05:52 PM
Chang Carmen	Director	Oct 02 '25	Sale	6.75	3,915	26,426	488,702	Oct 06 05:52 PM
Behbahani Ali	Director	Oct 02 '25	Option Exercise	0.01	682,468	6,825	2,385,055	Oct 06 05:52 PM
Behbahani Ali	Director	Oct 02 '25	Sale	6.75	3,915	26,426	488,702	Oct 06 05:52 PM
Yang Rick	Director	Oct 02 '25	Option Exercise	0.01	310,213	3,102	2,385,055	Oct 06 05:51 PM
Yang Rick	Director	Oct 02 '25	Sale	6.75	3,635	24,536	488,702	Oct 06 05:51 PM
Mathers Edward T	Director	Oct 02 '25	Option Exercise	0.01	310,213	3,102	2,385,055	Oct 06 05:50 PM
Mathers Edward T	Director	Oct 02 '25	Sale	6.75	3,635	24,536	488,702	Oct 06 05:50 PM
BASKETT FOREST	Director	Oct 02 '25	Option Exercise	0.01	992,680	9,927	1,961,234	Oct 06 05:50 PM
BASKETT FOREST	Director	Oct 02 '25	Sale	6.75	840	5,670	488,702	Oct 06 05:50 PM
NEA 18 Venture Growth Equity,	Director	Oct 02 '25	Option Exercise	0.01	124,085	1,241	2,385,055	Oct 06 05:49 PM
NEA 18 Venture Growth Equity,	Director	Oct 02 '25	Sale	6.75	3,355	22,646	1,654,334	Oct 06 05:49 PM
New Enterprise Associates 17,	Director	Oct 02 '25	Option Exercise	0.01	186,128	1,861	674,830	Oct 06 05:49 PM
New Enterprise Associates 17,	Director	Oct 02 '25	Sale	6.75	280	1,890	488,702	Oct 06 05:49 PM
New Enterprise Associates 16,	Director	Oct 02 '25	Option Exercise	0.01	372,255	3,723	1,160,234	Oct 06 05:48 PM
New Enterprise Associates 16,	Director	Oct 02 '25	Sale	6.75	280	1,890	787,979	Oct 06 05:48 PM
NEA 15 GP, LLC	Director	Oct 02 '25	Option Exercise	0.01	434,297	4,343	1,961,234	Oct 06 05:48 PM
NEA 15 GP, LLC	Director	Oct 02 '25	Sale	6.75	280	1,890	1,526,937	Oct 06 05:48 PM
New Enterprise Associates 15,	Director	Oct 02 '25	Option Exercise	0.01	434,297	4,343	1,961,234	Oct 06 05:48 PM
New Enterprise Associates 15,	Director	Oct 02 '25	Sale	6.75	280	1,890	1,526,937	Oct 06 05:48 PM
IMMELT JEFFREY R	Director	May 13 '25	Option Exercise	0.00	10,500	0	23,919	May 15 06:45 PM
ADKINS KEDRICK D JR	Director	May 13 '25	Option Exercise	0.00	10,500	0	16,443	May 15 06:39 PM
Kadre Manuel	Director	May 13 '25	Option Exercise	0.00	10,500	0	29,820	May 15 06:34 PM
Gooden Linda R	Director	May 13 '25	Option Exercise	0.00	10,500	0	16,443	May 15 06:27 PM
Sheehy Robert J	Director	May 13 '25	Option Exercise	0.00	10,500	0	15,255	May 15 06:20 PM
Makhzoumi Mohamad	Director	May 13 '25	Option Exercise	0.00	10,500	0	16,443	May 15 06:18 PM
Kraus Stephen	Director	May 13 '25	Option Exercise	0.00	10,500	0	16,444	May 15 06:15 PM
Manders Matthew G	Director	May 13 '25	Option Exercise	0.00	10,500	0	16,741	May 15 06:15 PM
Slavitt Andrew M	Director	May 13 '25	Option Exercise	0.00	10,500	0	18,529	May 15 06:07 PM
Scherman Jeffrey J	Chief Accounting Officer	May 12 '25	Sale	6.76	112	757	12,463	May 14 05:23 PM
Matushak Jay	Chief Financial Officer	May 12 '25	Sale	6.76	472	3,191	40,556	May 14 05:21 PM
Scherman Jeffrey J	Chief Accounting Officer	Mar 13 '25	Sale	6.74	1,020	6,875	12,587	Mar 17 08:40 PM
Scherman Jeffrey J	Chief Accounting Officer	Mar 14 '25	Sale	6.13	353	2,164	12,234	Mar 17 08:40 PM
Craig Jeffery Michael	GC & Corporate Secretary	Mar 13 '25	Sale	6.74	2,595	17,490	21,003	Mar 17 08:39 PM
Craig Jeffery Michael	GC & Corporate Secretary	Mar 14 '25	Sale	6.13	899	5,511	20,104	Mar 17 08:39 PM
Orozco Tomas	EVP, Consumer Care	Mar 13 '25	Sale	6.74	3,540	23,860	30,551	Mar 17 08:38 PM
Orozco Tomas	EVP, Consumer Care	Mar 14 '25	Sale	6.13	1,226	7,515	29,325	Mar 17 08:38 PM
Matushak Jay	Chief Financial Officer	Mar 13 '25	Sale	6.74	4,448	29,980	41,592	Mar 17 08:37 PM
Matushak Jay	Chief Financial Officer	Mar 14 '25	Sale	6.13	1,542	9,452	40,050	Mar 17 08:37 PM
Mikan George Lawrence III	CEO & President	Mar 13 '25	Sale	6.74	35,896	241,939	261,894	Mar 17 08:36 PM
Mikan George Lawrence III	CEO & President	Mar 14 '25	Sale	6.13	12,440	76,257	249,454	Mar 17 08:36 PM
Scherman Jeffrey J	Chief Accounting Officer	Mar 11 '25	Sale	6.85	427	2,925	8,482	Mar 13 09:55 PM
Scherman Jeffrey J	Chief Accounting Officer	Mar 12 '25	Sale	6.93	375	2,599	13,607	Mar 13 09:55 PM
Craig Jeffery Michael	GC & Corporate Secretary	Mar 12 '25	Sale	6.93	953	6,604	23,598	Mar 13 09:52 PM
Craig Jeffery Michael	GC & Corporate Secretary	Mar 11 '25	Sale	6.85	195	1,336	10,551	Mar 13 09:52 PM
Orozco Tomas	EVP, Consumer Care	Mar 12 '25	Sale	6.93	1,300	9,009	34,091	Mar 13 09:49 PM
Orozco Tomas	EVP, Consumer Care	Mar 11 '25	Sale	6.85	617	4,226	11,391	Mar 13 09:49 PM
Matushak Jay	Chief Financial Officer	Mar 12 '25	Sale	6.93	1,633	11,317	46,040	Mar 13 09:47 PM
Matushak Jay	Chief Financial Officer	Mar 11 '25	Sale	6.85	814	5,576	23,673	Mar 13 09:47 PM
Mikan George Lawrence III	CEO & President	Mar 12 '25	Sale	6.93	13,180	91,337	297,790	Mar 13 09:45 PM
Mikan George Lawrence III	CEO & President	Mar 11 '25	Sale	6.85	3,747	25,667	180,970	Mar 13 09:45 PM
Scherman Jeffrey J	Chief Accounting Officer	Mar 07 '25	Sale	7.19	620	4,458	7,813	Mar 11 09:51 PM
Scherman Jeffrey J	Chief Accounting Officer	Mar 10 '25	Sale	7.06	184	1,299	8,909	Mar 11 09:51 PM
Craig Jeffery Michael	GC & Corporate Secretary	Mar 07 '25	Sale	7.19	1,240	8,916	10,167	Mar 11 09:51 PM
Craig Jeffery Michael	GC & Corporate Secretary	Mar 10 '25	Sale	7.06	2	14	10,746	Mar 11 09:51 PM
Orozco Tomas	EVP, Consumer Care	Mar 07 '25	Sale	7.19	620	4,458	9,701	Mar 11 09:50 PM
Orozco Tomas	EVP, Consumer Care	Mar 10 '25	Sale	7.06	20	141	12,008	Mar 11 09:50 PM
Matushak Jay	Chief Financial Officer	Mar 07 '25	Sale	7.19	1,860	13,373	22,227	Mar 11 09:50 PM
Matushak Jay	Chief Financial Officer	Mar 10 '25	Sale	7.06	184	1,299	24,487	Mar 11 09:50 PM
Mikan George Lawrence III	CEO & President	Mar 07 '25	Sale	7.19	26,660	191,685	178,756	Mar 11 09:49 PM
Mikan George Lawrence III	CEO & President	Mar 10 '25	Sale	7.06	1,604	11,324	184,717	Mar 11 09:49 PM
Scherman Jeffrey J	Chief Accounting Officer	Jan 06 '25	Sale	7.33	1,368	10,027	5,942	Jan 08 08:58 PM
Craig Jeffery Michael	GC & Corporate Secretary	Jan 06 '25	Sale	7.33	2,486	18,222	7,558	Jan 08 08:57 PM
Matushak Jay	Chief Financial Officer	Jan 06 '25	Sale	7.33	4,970	36,430	17,747	Jan 08 08:55 PM
Orozco Tomas	EVP, Consumer Care	Jan 06 '25	Sale	7.33	1,233	9,038	7,830	Jan 08 08:54 PM
Mikan George Lawrence III	CEO & President	Jan 06 '25	Sale	7.33	31,798	233,079	146,539	Jan 08 08:53 PM
Mikan George Lawrence III	CEO & President	Dec 17 '24	Sale	4.18	16,803	70,237	83,029	Dec 18 09:15 PM

Open in Screener

MBX

MBX Biosciences Inc

Oct 06 • 04:00PM ET

16.26

-0.43 -2.58 %

Healthcare • Biotechnology • USA • NASD

MBX MBX Biosciences Inc daily Stock Chart

Held by: VTI IWM IWN SCHA VXF VTWO FESM IWC SBIO BBC

Index	RUT	P/E	-	EPS (ttm)	-2.31	Insider Own	53.79%	Shs Outstand	33.59M	Perf Week	-9.36%
Market Cap	727.07M	Forward P/E	-	EPS next Y	-2.80	Insider Trans	2.88%	Shs Float	20.67M	Perf Month	40.78%
Enterprise Value	502.83M	PEG	-	EPS next Q	-0.70	Inst Own	42.94%	Short Float	20.45%	Perf Quarter	24.41%
Income	-77.02M	P/S	-	EPS this Y	53.36%	Inst Trans	2.76%	Short Ratio	3.82	Perf Half Y	169.21%
Sales	0.00M	P/B	2.49	EPS next Y	-3.05%	ROA	-52.32%	Short Interest	4.23M	Perf YTD	-11.77%
Book/sh	6.53	P/C	3.23	EPS next 5Y	17.25%	ROE	-56.28%	52W High	27.50 -40.87%	Perf Year	-30.98%
Cash/sh	5.03	P/FCF	-	EPS past 3/5Y	-53.83% -	ROIC	-35.05%	52W Low	4.81 238.26%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.73% 11.16%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.89	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	19.50	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	54.55	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	19.50	EPS Q/Q	-22.16%	SMA20	12.14%	Beta	1.08	Target Price	60.29
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	17.25%	Rel Volume	0.96	Prev Close	16.69
Employees	43	LT Debt/Eq	0.00	Earnings	Aug 07 BMO	SMA200	36.08%	Avg Volume	1.11M	Price	16.26
IPO	Sep 13, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	21.06% -	Trades		Volume	1,062,766	Change	-2.58%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-15-25	Resumed	Jefferies	Buy	$36
Aug-05-25	Initiated	Mizuho	Outperform	$38
Jul-16-25	Initiated	Oppenheimer	Outperform	$38
Apr-10-25	Initiated	Citizens JMP	Mkt Outperform	$38
Oct-08-24	Initiated	Stifel	Buy	$40
Oct-08-24	Initiated	JP Morgan	Overweight	$30
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$44

Sep-29-25 08:00AM	MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum (GlobeNewswire)
Sep-24-25 09:15PM	MBX Biosciences Announces Pricing of Upsized Public Offering (GlobeNewswire) +6.01% -13.78%
Sep-23-25 09:55AM	Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 88.55%: Read This Before Placing a Bet (Zacks) -5.20%
06:45AM	MBX to advance hypoparathyroidism drug to Phase III trial (Clinical Trials Arena)
04:54AM	FDA clears under-the-skin Keytruda; MBX shares double on study data (BioPharma Dive)
04:14PM	Loading…
Sep-22-25 04:14PM	MBX Biosciences Announces Proposed Public Offering (GlobeNewswire) +100.00%
04:03PM	MBX Biosciences Stock Doubles On Promising New Thyroid Disease Treatment (Investor's Business Daily)
09:34AM	MBX Biosciences Catapults 125%, Hitting A Nine-Month High, On Thyroid Drug Promise (Investor's Business Daily)
08:28AM	MBX Biosciences' Experimental Drug Shows Promise In Hypoparathyroidism Study (Benzinga)
07:00AM	MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension (GlobeNewswire)
Sep-19-25 04:18PM	MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22 (GlobeNewswire)
Sep-15-25 12:15PM	Top 3 Biotech Stocks to Watch According to BofA Global Research (Investing.com)
Sep-04-25 08:00AM	MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity (GlobeNewswire) -10.28%
Aug-20-25 12:13AM	MBX Biosciences Submits IND for Once-Monthly Obesity Drug (Insider Monkey)
Aug-07-25 08:00AM	MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
09:37AM	Loading…
Aug-05-25 09:37AM	Block downgraded, Wayfair upgraded: Wall Street's top analyst calls (The Fly)
Jun-23-25 08:00AM	MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development (GlobeNewswire)
Jun-16-25 08:00AM	MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity (GlobeNewswire)
Jun-10-25 08:00AM	MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions (GlobeNewswire)
May-20-25 08:00AM	MBX Biosciences to Participate in June Investor Conferences (GlobeNewswire)
May-15-25 07:16AM	Microbix Reports Results for Q2 Fiscal 2025 (GlobeNewswire)
May-13-25 07:00AM	Microbix & Aurevia Introduce Novel EQA Scheme (GlobeNewswire) -7.81%
May-12-25 08:00AM	MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-08-25 07:00AM	Microbix Schedules Release of Results for Q2 Fiscal 2025 (GlobeNewswire) +8.13%
May-05-25 07:00AM	Microbix's Clot-Buster Drug Project Advances (GlobeNewswire)
Apr-22-25 08:00AM	MBX Biosciences to Participate in Citizens and RBC May Investor Conferences (GlobeNewswire) +13.09%
Apr-07-25 08:00AM	MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors (GlobeNewswire)
Mar-26-25 08:00AM	MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-17-25 08:00AM	MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-05-25 08:00AM	MBX Biosciences Announces Additions to Leadership Team (GlobeNewswire)
08:00AM	Loading…
Mar-03-25 08:00AM	MBX Biosciences Completes Enrollment in Phase 2 Avail Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism (GlobeNewswire) +5.62%
Feb-18-25 08:00AM	MBX Biosciences to Participate in March Investor Conferences (GlobeNewswire)
Jan-23-25 08:00AM	MBX Biosciences to Participate in Upcoming February Investor Conferences (GlobeNewswire) +8.11%
Jan-07-25 11:47AM	MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action (Benzinga) -10.32%
07:00AM	MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia (GlobeNewswire)
Dec-18-24 08:00AM	MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-02-24 08:00AM	MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism (GlobeNewswire) -6.59%
Nov-18-24 08:00AM	MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia (GlobeNewswire) -6.76%
Nov-07-24 08:00AM	MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-28-24 08:00AM	MBX Biosciences to Participate in Upcoming November Investor Conferences (GlobeNewswire) -6.50%
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks)
Sep-30-24 08:00AM	MBX Biosciences Presents MBX 2109 Phase 2 Avail Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting (GlobeNewswire) +8.48%
Sep-23-24 07:05PM	Deep Track Capital, LP's Strategic Acquisition in MBX Biosciences Inc (GuruFocus.com)
Sep-18-24 03:19AM	OrbiMed Advisors LLC Acquires New Stake in MBX Biosciences Inc (GuruFocus.com)
Sep-16-24 04:05PM	MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -8.46%
Sep-12-24 07:11PM	MBX Biosciences Announces Pricing of Initial Public Offering (GlobeNewswire)

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heron Patrick J	Director	Sep 26 '25	Buy	18.00	666,666	11,999,988	5,219,440	Sep 30 04:59 PM
Pescovitz Ora H.	Director	Apr 08 '25	Buy	5.89	7,693	45,312	24,329	Apr 10 08:39 AM
GORDON CARL L	Director	Feb 18 '25	Buy	10.84	143,170	1,551,963	3,255,000	Feb 19 05:56 PM
GORDON CARL L	Director	Feb 14 '25	Buy	9.87	47,502	468,793	3,205,930	Feb 19 05:56 PM
ORBIMED ADVISORS LLC	Director	Feb 18 '25	Buy	10.84	143,170	1,551,963	3,255,000	Feb 19 05:52 PM
ORBIMED ADVISORS LLC	Director	Feb 14 '25	Buy	9.87	47,502	468,793	3,205,930	Feb 19 05:52 PM
Hawryluk P. Kent	President & CEO	Feb 04 '25	Buy	10.69	50,000	534,500	448,277	Feb 05 04:17 PM

Open in Screener

KRRO

Korro Bio Inc

Oct 06 • 04:00PM ET

43.70

-2.52 -5.45 %

Healthcare • Biotechnology • USA • NASD

Peers: BEAM EDIT NTLA CRSP RGNX FDMT VYGR ARVN SGMO CRBU

| Held by: IWM VTI IWN LFSC VXF VTWO IWC ITOT AVSC VHT

Index	RUT	P/E	-	EPS (ttm)	-9.75	Insider Own	43.88%	Shs Outstand	9.39M	Perf Week	2.10%
Market Cap	410.38M	Forward P/E	-	EPS next Y	-9.99	Insider Trans	0.00%	Shs Float	5.27M	Perf Month	31.71%
Enterprise Value	357.65M	PEG	-	EPS next Q	-2.59	Inst Own	61.13%	Short Float	28.05%	Perf Quarter	221.80%
Income	-91.36M	P/S	65.35	EPS this Y	-8.27%	Inst Trans	-7.19%	Short Ratio	7.73	Perf Half Y	203.89%
Sales	6.28M	P/B	3.57	EPS next Y	1.54%	ROA	-42.49%	Short Interest	1.48M	Perf YTD	14.79%
Book/sh	12.26	P/C	4.22	EPS next 5Y	-7.79%	ROE	-58.34%	52W High	98.00 -55.41%	Perf Year	32.50%
Cash/sh	10.37	P/FCF	-	EPS past 3/5Y	57.64% 21.83%	ROIC	-58.07%	52W Low	10.29 324.68%	Perf 3Y	-3.96%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-45.55% -39.89%	Gross Margin	27.67%	Volatility	12.04% 10.97%	Perf 5Y	-91.15%
Dividend TTM	-	EV/Sales	56.95	EPS Y/Y TTM	61.73%	Oper. Margin	-1569.08%	ATR (14)	3.89	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.98	Sales Y/Y TTM	-	Profit Margin	-1454.47%	RSI (14)	65.61	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.98	EPS Q/Q	-12.99%	SMA20	15.59%	Beta	5.15	Target Price	93.88
Payout	-	Debt/Eq	0.39	Sales Q/Q	-	SMA50	61.75%	Rel Volume	1.51	Prev Close	46.22
Employees	104	LT Debt/Eq	0.37	Earnings	Aug 12 BMO	SMA200	86.09%	Avg Volume	191.17K	Price	43.70
IPO	Oct 03, 2019	Option/Short	No / Yes	EPS/Sales Surpr.	-6.80% 200.60%	Trades		Volume	287,070	Change	-5.45%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$74
Apr-16-25	Initiated	Chardan Capital Markets	Buy	$25
Jan-10-25	Initiated	Oppenheimer	Outperform	$155
Oct-21-24	Initiated	Raymond James	Strong Buy	$153
Aug-14-24	Initiated	William Blair	Outperform	$180
Mar-28-24	Reiterated	H.C. Wainwright	Buy	$100 → $115
Feb-27-24	Initiated	BMO Capital Markets	Outperform	$120
Dec-04-23	Initiated	H.C. Wainwright	Buy	$100
Nov-29-23	Initiated	RBC Capital Mkts	Outperform	$70
Nov-10-23	Initiated	Piper Sandler	Overweight	$180
Feb-15-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Feb-13-23	Downgrade	Cowen	Outperform → Market Perform
Sep-22-21	Downgrade	Goldman	Buy → Neutral	$12 → $9
Jan-27-21	Upgrade	JP Morgan	Neutral → Overweight	$56
Dec-22-20	Initiated	B. Riley Securities	Buy	$79
Jul-14-20	Initiated	Oppenheimer	Outperform	$36
May-18-20	Downgrade	JP Morgan	Overweight → Neutral	$27
Oct-28-19	Initiated	JP Morgan	Overweight	$25
Oct-28-19	Initiated	Goldman	Buy	$30
Oct-28-19	Initiated	Cowen	Outperform

Show Previous Ratings

Sep-02-25 04:30PM	Korro to Participate in Upcoming Investor and Scientific Conferences (GlobeNewswire) +17.25%
Aug-12-25 07:00AM	Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) +6.25%
Jul-21-25 08:00AM	Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110 (GlobeNewswire)
May-14-25 04:05PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) -9.26%
May-09-25 10:31AM	Korro Bio price target lowered to $53 from $130 at H.C. Wainwright (TipRanks)
04:30PM	Loading…
May-07-25 04:30PM	Korro Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -5.85% +10.55%
Apr-01-25 07:30AM	Korro Appoints Biotech Industry Veteran, Loic Vincent, Ph.D., as Chief Scientific Officer (GlobeNewswire) -8.39%
07:30AM	Korro Appoints Biotech Industry Veteran, Lo c Vincent, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Mar-28-25 06:18PM	Korro Bio: Promising Early Stage RNA Editing Company (Seeking Alpha) -5.11%
Mar-18-25 07:00AM	Korro Reports Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-17-25 07:26AM	FDA grants orphan drug status for Korro Bio's AATD therapy (Pharmaceutical Business Review)
Mar-14-25 08:00AM	KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
Feb-26-25 08:00AM	Korro to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Jan-13-25 08:00AM	Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update (GlobeNewswire) +8.20%
Jan-07-25 08:00AM	Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.23%
08:00AM	Loading…
Dec-10-24 08:00AM	CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors (GlobeNewswire)
Nov-21-24 04:01PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.70%
07:30AM	Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
Nov-14-24 08:00AM	Korro to Present at the Jefferies London Healthcare Conference (GlobeNewswire) -9.65%
Nov-12-24 04:05PM	Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -11.37% -15.55%
Nov-04-24 07:25AM	Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board (GlobeNewswire)
Oct-21-24 04:15PM	Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space. (Investor's Business Daily) -5.22% -7.70%
Oct-16-24 04:20PM	Wave Life Sciences Just Edited RNA. Why Its Key Rival, Korro Bio, Skyrocketed. (Investor's Business Daily) +93.66%
Sep-30-24 08:00AM	Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society (GlobeNewswire)
Sep-16-24 08:00AM	Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates (GlobeNewswire)
Sep-10-24 08:00AM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-28-24 08:00AM	Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors (GlobeNewswire)
Aug-27-24 08:00AM	Korro to Participate in Upcoming September Investor and Scientific Conferences (GlobeNewswire)
Aug-13-24 04:01PM	Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +9.21%
Jul-01-24 08:00AM	Korro Joins the Russell 2000 , Russell 3000 , and Russell Microcap Indexes (GlobeNewswire)
12:53PM	Loading…
Jun-25-24 12:53PM	KRRO Stock Earnings: Korro Bio Beats EPS for Q4 2023 (InvestorPlace)
May-30-24 04:01PM	Korro to Participate in Upcoming June Investor and Scientific Conferences (GlobeNewswire)
May-20-24 02:30PM	Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference (GlobeNewswire)
May-14-24 10:55PM	KRRO Stock Earnings: Korro Bio Beats EPS for Q1 2024 (InvestorPlace) +5.43%
04:01PM	Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-18-24 08:30AM	Korro Announces $70 Million Private Placement (GlobeNewswire)
Apr-01-24 04:01PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.90%
Mar-26-24 04:01PM	Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) +18.43%
Feb-27-24 09:55AM	Wall Street Analysts Believe Korro Bio, Inc. (KRRO) Could Rally 86.94%: Here's is How to Trade (Zacks) -6.08%
08:00AM	Korro to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-09-24 09:55AM	Does Korro Bio, Inc. (KRRO) Have the Potential to Rally 59.66% as Wall Street Analysts Expect? (Zacks)
Jan-18-24 08:00AM	Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio (GlobeNewswire) -5.98%
Jan-04-24 08:00AM	Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-07-23 08:00AM	Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire) -14.67%
Nov-28-23 08:00AM	Korro Bio Appoints Dr. Rachel Meyers to Board of Directors (GlobeNewswire) +6.45%
Nov-03-23 03:31PM	UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire) +5.94%
12:19PM	Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire)
Aug-10-23 04:01PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results (Business Wire)
Jul-17-23 11:59AM	Frequency (FREQ) Up 77% on Merger Deal With Korro Bio (Zacks) -12.66%
Jul-14-23 11:22AM	Why Are Frequency Therapeutics Shares Surging Today (Benzinga) +77.47%
06:30AM	Korro Bio and Frequency Therapeutics Announce Merger Agreement (Business Wire)
May-12-23 04:01PM	Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results (Business Wire) -5.17%
Mar-10-23 07:30AM	Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-27-23 07:30AM	Frequency Therapeutics to Participate at Upcoming March Investor Conferences (Business Wire) +5.40%
Feb-13-23 01:55PM	Hearing loss startup to cut more than half of staff in wake of trial failure (American City Business Journals) -80.54%
11:17AM	Frequency Therapeutics' Lead Hearing Loss Program Flunks, Shifts Focus To Multiple Sclerosis, Shares Plunge (Benzinga)
08:05AM	Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire)
Dec-19-22 07:30AM	Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program (Business Wire)
Dec-15-22 07:30AM	Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Companys Second Therapeutic Candidate for Sensorineural Hearing Loss (Business Wire)
Nov-17-22 07:30AM	Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results (Business Wire) -10.05%
Nov-08-22 04:05PM	Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results (Business Wire) -9.51%
Oct-12-22 07:30AM	Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire) +7.47%
Aug-30-22 07:30AM	Frequency Therapeutics to Participate in September Investor and Medical Conferences (Business Wire)
Aug-09-22 04:05PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results (Business Wire) -11.11% +9.00%
Jun-24-22 09:03AM	Frequency Therapeutics (NASDAQ:FREQ) one-year losses have grown faster than shareholder returns have fallen, but the stock jumps 41% this past week (Simply Wall St.) -7.59%
May-25-22 12:00PM	Frequency Therapeutics, Inc. (FREQ) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-18-22 07:30AM	Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference (Business Wire) -9.02%
May-04-22 04:30PM	Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results (Business Wire)
Apr-22-22 07:30AM	Frequency Therapeutics to Participate in B. Riley Securities Neuro & Ophthalmology Investor Conference (Business Wire)
Apr-08-22 05:00PM	Frequency Exchange Corp. Virtually Closes the Market (PR Newswire) -8.82%
Mar-15-22 07:30AM	Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results (Business Wire) +15.29%
Mar-10-22 06:35PM	Poseida Therapeutics, Inc. (PSTX) Beats Q4 Earnings and Revenue Estimates (Zacks) -13.70%
Feb-28-22 07:30AM	Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences (Business Wire)
Jan-14-22 05:43AM	One Frequency Therapeutics, Inc. (NASDAQ:FREQ) insider upped their stake in the previous year (Simply Wall St.)
Jan-04-22 07:30AM	Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-28-21 02:38AM	Destra Investment Trust Buys ThredUp Inc, Etsy Inc, Riskified, Sells , , 2U Inc (GuruFocus.com) +5.28%
Dec-09-21 01:18PM	Frequency Therapeutics' Hearing Loss Candidate Shows Improved Speech Perception In Noise (Benzinga)
07:30AM	Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise (Business Wire)
Nov-30-21 05:53AM	Frequency Therapeutics (NASDAQ:FREQ) investors are sitting on a loss of 81% if they invested a year ago (Simply Wall St.)
Nov-15-21 12:25PM	Frequency Therapeutics, Inc. (FREQ) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results (Business Wire)
Nov-09-21 07:30AM	Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis (Business Wire)
Nov-08-21 03:00PM	Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-27-21 07:30AM	Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program (Business Wire)
Oct-21-21 07:30AM	Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint (Business Wire)
Oct-01-21 08:23AM	Do Insiders Own Lots Of Shares In Frequency Therapeutics, Inc. (NASDAQ:FREQ)? (Simply Wall St.)
Sep-22-21 11:18AM	Frequency Therapeutics' New Data Of Hearing Loss Candidate Fails To Impress Investors (Benzinga)
07:30AM	Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points (Business Wire)
Sep-08-21 07:30AM	Frequency Therapeutics to Present at Upcoming Investor Conferences (Business Wire)
Aug-30-21 05:10PM	Lifshitz Law Firm, P.C. Announces Investigations of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Frequency Therapeutics, Inc. (NasdaqGS: FREQ), RLX Technology Inc. (NYSE: RLX), and Washington Prime Group, Inc. (NYSE: WPG) (ACCESSWIRE)
Aug-12-21 04:06PM	Moore Kuehn, PLLC Encourages Investors of FREQ to Contact Law Firm (Newsfile)
08:45AM	Frequency Therapeutics, Inc. (FREQ) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results (Business Wire)
Aug-04-21 03:00PM	Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for (Zacks)
Aug-02-21 03:05PM	CLASS ACTION UPDATE for JRVR, FREQ and QFIN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders (ACCESSWIRE)
02:30PM	Final Deadline Alert: Frequency Therapeutics, Inc. (FREQ) Class Action and Last Chance for Investors to Actively Participate - Bronstein, Gewirtz & Grossman, LLC (ACCESSWIRE)
12:30PM	SHAREHOLDER ALERT: FREQ RKT QFIN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines (ACCESSWIRE)
12:30PM	FINAL DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (ACCESSWIRE)
11:00AM	FREQ Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Frequency Therapeutics, Inc. (FREQ) Shareholders of Class Action and Lead Plaintiff Deadline: August 2, 2021 (ACCESSWIRE)
10:00AM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FREQ, RKT and BZ (ACCESSWIRE)

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Agarwal Vineet	Chief Financial Officer	Nov 11 '24	Option Exercise	11.68	800	9,344	800	Nov 12 07:40 PM
Agarwal Vineet	Chief Financial Officer	Nov 11 '24	Sale	70.00	800	56,000	0	Nov 12 07:40 PM
Agarwal Vineet	Officer	Nov 11 '24	Proposed Sale	70.00	800	56,000		Nov 12 08:28 AM
Agarwal Vineet	Chief Financial Officer	Oct 17 '24	Option Exercise	11.99	10,216	122,468	10,216	Oct 18 07:43 PM
Agarwal Vineet	Chief Financial Officer	Oct 17 '24	Sale	78.26	10,216	799,527	0	Oct 18 07:43 PM
Agarwal Vineet	Officer	Oct 17 '24	Proposed Sale	78.26	10,216	799,527		Oct 17 04:22 PM
Colletti Steve	Former Officer	Oct 16 '24	Proposed Sale	88.67	13,821	1,225,450		Oct 16 01:05 PM

NEUE

NeueHealth Inc

MBX

MBX Biosciences Inc

KRRO

Korro Bio Inc

Upgrade your FINVIZ experience